PERHA PHARMACEUTICALS SAS
Desconocido
DOWN-AUTONOMY: LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome.
PERHA PHARMACEUTICALS SAS
tramitó un
HORIZON EUROPE:
HORIZON-EIC-2022-ACCELERATOR-01
All people with Down Syndrome (DS) suffer from a certain level of impaired learning and memory (cognitive disorders) from childhood onwards,...
2022-11-16 - 2026-06-30 | Financiado
2022-11-16 - 2026-06-30 | Financiado
GO-DS21: Gene overdosage and comorbidities during the early lifetime in Down Syndrome
PERHA PHARMACEUTICALS SAS
participó en un
H2020:
H2020-SC1-BHC-2018-2020
The aim of the project is to elucidate etiological mechanisms involved in the appearance of obesity, and intellectual disability comorbiditi...
2019-11-22 - 2025-06-30 | Financiado
2019-11-22 - 2025-06-30 | Financiado
* No se disponen de datos de la empresa actual.